KRAS and colorectal cancer: The first approved, EGFR inhibitor erlotinib in combination with gemcitabine, gave a modest survival benefit compared to gemcitabine alone and was effectively abandoned by the community after negative data in KRAS-mutant colorectal cancer emerged (Luo, 2021; Moore et al., 2007).